Publications by authors named "Treeprasertsuk S"
Background: Despite the popularity of a ketogenic diet, no randomized, controlled trials have evaluated its efficacy on metabolic dysfunction-associated steatotic liver disease (MASLD) progression.
Methods: We conducted an 8-week, open-label, randomized controlled trial involving 24 patients with MASLD who were randomly assigned to either the home delivery ketogenic diet or a nutrition education program on adherence to the DASH diet. The primary outcome was a reduction in hepatic steatosis as measured by transient elastography.
Background: Clot waveform analysis (CWA) provides a global assessment of hemostasis and may be useful for patients with cirrhosis with complex hemostatic abnormalities. This study aimed to assess the association between prothrombin time (PT-) and activated partial thromboplastin time (aPTT-) based CWA parameters and cirrhosis severity and prospectively evaluate the role of CWA in predicting mortality and acute decompensation (AD) over 1 year.
Methods: This prospective study included adult patients with cirrhosis between June 2021 and December 2023 at Chulalongkorn University Hospital.
Background: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver cancer attributable to metabolic risk factors, including high body mass index (BMI) and high fasting plasma glucose (FPG) levels, between 1990 and 2021.
Methods: The total number and age-standardized rates of deaths and disability-adjusted life years (DALYs) from primary liver cancer attributable to each metabolic risk factor were extracted from the Global Burden of Disease Study 1990-2021.
Background & Aims: Acute-on-chronic liver failure is a syndrome characterized by organ failure and high short-term mortality. The lack of reliable biomarkers for the early detection of acute-on-chronic liver failure is a significant challenge. Endothelial dysfunction plays a key role in the development of organ failure.
View Article and Find Full Text PDFArticle Synopsis
- Acute liver failure (ALF) in dengue patients is uncommon but highly fatal; identifying those at risk is crucial for improving survival rates.
- A study involving 2532 dengue patients revealed that factors like international normalized ratio, bilirubin, albumin, and creatinine can predict the likelihood of ALF and in-hospital mortality in patients with dengue-induced severe hepatitis (DISH).
- Several prognostic scores, including the MELD score and ALBI score, effectively predicted ALF and mortality, demonstrating high sensitivity and specificity in clinical assessments.
Background: Metabolic risk factors are a significant cause of global burden among adolescents and young adults, but there is a lack of attention to the burden attributable to these metabolic risk factors globally.
Aims: This study aims to provide comprehensive estimates of five important metabolic risk factors and the attributable disease burden in people aged 15-39 years from 1990 to 2021, based on the Global Burden of Disease Study (GBD) database.
Methods: Global total deaths and disability-adjusted life years (DALYs) were used to describe the burden attributable to five common metabolic risk factors, including high fasting plasma glucose (FPG), high low-density lipoprotein cholesterol (LDL-C), high systolic blood pressure (SBP), high body mass index (BMI), and kidney dysfunction, in adolescents and young adults.
Article Synopsis
- - Obesity is a major global health concern, with a significant rise in deaths and disability-adjusted life years (DALYs) linked to high body mass index (BMI) from 1990 to 2021, notably increasing by over 2.5 times for both genders.
- - The main health issues associated with high BMI in 2021 included diabetes, heart disease, and stroke, with low-middle socio-demographic index (SDI) countries experiencing the largest increase in disease burden.
- - The findings call for urgent monitoring and intervention efforts to address the growing health impact of high BMI from 1990 to 2021, especially given the stable death rates for women and rising rates for men.
Article Synopsis
- Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
- They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
- The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.
Article Synopsis
- Metabolic dysfunction-associated fatty liver disease (MAFLD) is a rising cause of chronic liver disease globally, prompting the need for dietary intervention strategies.
- A panel of 55 international experts conducted a study to reach a consensus on dietary modifications for preventing MAFLD, covering various aspects from epidemiology to management.
- Recommended strategies include following a balanced diet, increasing whole grains and plant-based foods, and reducing red meat and processed foods, along with advocating for physical activity and possibly maintaining Mediterranean or DASH diets.
Background: Common metabolic diseases, such as type 2 diabetes mellitus (T2DM), hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic liver disease (MASLD), have become a global health burden in the last three decades. The Global Burden of Disease, Injuries, and Risk Factors Study (GBD) data enables the first insights into the trends and burdens of these metabolic diseases from 1990 to 2021, highlighting regional, temporal and differences by sex.
Methods: Global estimates of disability-adjusted life years (DALYs) and deaths from GBD 2021 were analyzed for common metabolic diseases (T2DM, hypertension, obesity, hypercholesterolemia, and MASLD).
Background And Aims: With ultrasound sensitivity limited in hepatocellular carcinoma (HCC) surveillance and few prospective studies on non-contrast abbreviated MRI (NC-AMRI), this study aimed to assess its diagnostic performance in detecting HCC.
Methods: This prospective study involved cirrhotic patients with contrast-enhanced MRI (CE-MRI) Liver Imaging Reporting and Data System (LI-RADS) LR-3 and LR-4 observations detected during HCC surveillance. Patients underwent average 3 complete CE-MRI rounds at 3-6 months interval, with approximately 12-month follow-up.
Article Synopsis
- The review highlights the recent approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH), a liver disease related to obesity, emphasizing its potential impact on global health and the need for a multidisciplinary management approach.* -
- Resmetirom is effective in treating MASH and has received FDA approval, but its safety, potential adverse events, and effectiveness across different populations require further study to optimize patient outcomes.* -
- A comprehensive treatment strategy is recommended, combining resmetirom with lifestyle changes and metabolic and bariatric surgery (MBS), to enhance liver and overall health for individuals suffering from MASH.*
Background & Aims: Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) face a multifaceted disease burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the burden of liver disease in patients with NAFLD and the relationship between experience of stigma and HRQL.
Methods: Members of the Global NASH Council created a survey about disease burden in NAFLD.
Article Synopsis
- MAFLD (Metabolic Dysfunction-Associated Fatty Liver Disease) is becoming more common, and it can lead to serious liver problems called MAFLD-ACLF, but what affects patient recovery isn't fully known yet.
- In a study, researchers looked at data from patients with MAFLD-ACLF to understand their health conditions and see who survived after 90 days, finding that about 51% of patients did survive.
- They discovered new scoring systems to better predict survival, which included factors like diabetes and the causes of liver damage, and these new scores worked better than older ones.
Introduction: Hepatocellular carcinoma (HCC) constitutes the majority of liver cancers and significantly impacts global cancer mortality. While ultrasound (US) with or without alpha-fetoprotein is the mainstay for HCC surveillance, its limitations highlight the necessity for more effective surveillance tools. Therefore, this review explores evolving imaging modalities and abbreviated magnetic resonance imaging (MRI) (AMRI) protocols as promising alternatives, addressing challenges in HCC surveillance.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is a significant global health concern, especially as advanced fibrosis (F≥2) increases mortality risks.
- It’s crucial for primary care providers to refer patients with significant fibrosis to specialists, highlighting the need for effective noninvasive risk assessment tools.
- The study evaluates the Steatosis-associated fibrosis estimator (SAFE) against other tools, like FIB-4 and NAFLD fibrosis score (NFS), suggesting that using SAFE earlier could reduce the misclassification of patients at risk for serious liver issues.
Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.
Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.
Liver fibrosis is a pathological condition characterized by the abnormal proliferation of liver tissue, subsequently able to progress to cirrhosis or possibly hepatocellular carcinoma. The development of artificial intelligence and deep learning have begun to play a significant role in fibrosis detection. This study aimed to develop SMART AI-PATHO, a fully automated assessment method combining quantification of histopathological architectural features, to analyze steatosis and fibrosis in nonalcoholic fatty liver disease (NAFLD) core biopsies and employ Metavir fibrosis staging as standard references and fat assessment grading measurement for comparison with the pathologist interpretations.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates whether tracking changes in liver stiffness measurements (LSM) over time can better predict liver-related events (LRE) in patients with compensated advanced chronic liver disease (cACLD) compared to just looking at the most recent LSM.
- Analyzing data from 480 patients across five countries, researchers found that while a higher current LSM was linked to a higher risk of LRE, changes in LSM over time were not significantly predictive.
- The conclusion is that once the latest LSM value is available, previous LSM measurements do not provide any additional predictive benefit for LRE in cACLD patients.
Background And Aims: Chronic viral hepatitis B (CHB)-infected patients occasionally develop cirrhosis despite having persistent viral suppression with antiviral therapy. We aimed to identify risk factors for developing cirrhosis in hepatitis B virus (HBV)-suppressed patients.
Methods: We conducted a case-control study involving 120 noncirrhotic CHB-infected patients achieving viral suppression with antiviral treatment, with 40 cases developing cirrhosis and 80 age-, sex-, and Fibrosis-4 (FIB-4)-matched controls.
Introduction: Data on the relationship between bacterial translocation, hepatic encephalopathy (HE), and mortality are scarce. This study aimed to assess the association between bacterial DNA (bactDNA) translocation, inflammatory response, ammonia levels, and severity of HE in patients with cirrhosis, as well as the role of bactDNA translocation in predicting mortality.
Methods: Cirrhotic patients without bacterial infection were prospectively enrolled between June 2022 and January 2023.
Article Synopsis
- The study aimed to evaluate the relationship between ammonia levels and liver-related complications (LRCs) in patients with acute-on-chronic liver failure (ACLF).
- Higher ammonia levels were found in ACLF patients with LRCs, especially those experiencing overt hepatic encephalopathy (HE) and ascites, but not bacterial infections.
- Baseline arterial ammonia levels were identified as an independent predictor of 30-day mortality, but they did not predict the development of new LRCs within that timeframe.
Article Synopsis
- End-stage liver disease (ESLD) significantly increases mortality rates, particularly when complicated by infections, which are common in these patients.
- Infections can worsen liver function and are a major cause of deteriorating health in ESLD patients.
- There is a critical need for standardized protocols for diagnosis and management of ESLD with infections, especially in the Asia Pacific region, where the prevalence is high due to factors like hepatitis B and rising cases of alcohol and NAFLD.
Neck circumference is an attractive method for determining metabolic profiles and has many advantages over waist circumference. However, the correlation between neck circumference and hepatic fibrosis has not been evaluated. The aim of this study was to evaluate the correlation between neck circumference and hepatic fibrosis and define the optimal cut-off point for neck circumference to determine hepatic fibrosis.
View Article and Find Full Text PDF